Investing.comCodex · 实盘不做把握 5/10
北京时间·🕒 发布 19:12:41时区推断·⟳ 抓取 19:23:28·⚡ 决策 07-27 19:25:05 +1m37s·91.9 天前
Gossamer计划9月提交seralutinib PAH新药申请并收回全球权益
FDA把PROSERA统计显著性与疗效幅度列为审评问题而非受理问题，降低的是NDA递交层面的障碍，不等于批准概率已明显提升。
📄 原文Investing.com↗ 原文
Gossamer Bio plans September NDA submission for seralutinib
Oil prices tumble over 8% amid halt to fighting between U.S., Iran SAN DIEGO - Gossamer Bio, Inc. (NASDAQ:GOSS) plans t…
不做 Gossamer Bio（GOSS.US）
不做：9月NDA路径已在5月预告，本次只是递交层面障碍下降；三期主终点未达预设阈值、Chiesi终止合作和反向拆股/稀释背景使事件净影响不够清晰，盘前微盘跳空也难给正期望入场。
展开详情(成交明细 / 研究档案 / 原文全文 / 决策记录链)
研究档案
消息传播链
- 公司一季报已披露已安排6月Pre-NDA Type B会议，并在会议结果允许时计划2026年9月提交seralutinib PAH NDA。
- 公司称已收到FDA会议纪要，FDA将统计显著性和疗效幅度视为审评问题而非受理问题，并确认计划9月递交NDA。
- Investing.com在美股盘前转述公司更新，detect约11分钟后抓到，传播较新但并非一手首发。市场反应:美股仍处盘前，未用作可执行连续交易价格。
关键理由
- FDA把PROSERA统计显著性与疗效幅度列为审评问题而非受理问题，降低的是NDA递交层面的障碍，不等于批准概率已明显提升。
- 9月递交NDA和2027年三季度潜在PDUFA时间表在5月一季报中已预告，本次新增信息更多是路径确认而非短线商业化兑现。
- Chiesi终止合作后Gossamer收回全球权益，但现金仅约5700万美元，且仍面临反向拆股、稀释性换债和后续开发/商业化资金压力。
主要风险
- 若盘前资金只交易“FDA不阻止递交”标题，微盘生物科技股可能出现高波动跳空，AVOID可能错过短线投机反应。
- PROSERA三期主终点此前未达到预设统计阈值，FDA最终可批准性仍是核心不确定性。
反向证据
- 做多前查反向 · 来源 web · 日期 2026-02-23 · 影响 weakens
PROSERA三期主终点未达到预设统计阈值，FDA允许递交不等于批准概率足以支撑追多。
检索:Gossamer Bio seralutinib PROSERA failed primary endpoint p=0.032 FDA approval risk 原文 ↗ - 做多前查反向 · 来源 web · 日期 2026-07-27 · 影响 weakens
Chiesi合作终止虽提高权益占比，但也去掉外部合作背书；公司现金5700万美元且有反向拆股和换债稀释背景。
检索:Gossamer Bio Chiesi collaboration termination seralutinib cash reverse split debt exchange 原文 ↗
原文全文
展开原文 · 2,205 字
Oil prices tumble over 8% amid halt to fighting between U.S., Iran
SAN DIEGO - Gossamer Bio, Inc. (NASDAQ:GOSS) plans to submit a New Drug Application for seralutinib in pulmonary arterial hypertension in September 2026, according to a press release statement issued Monday.
The clinical-stage biopharmaceutical company held a Pre-NDA Type B meeting with the U.S. Food and Drug Administration in mid-June 2026 and received official meeting minutes. The FDA characterized the degree of statistical significance and magnitude of treatment effect observed in the Phase 3 PROSERA study as review issues rather than filing issues, the company stated.
The planned NDA submission will be supported by the Phase 3 PROSERA study plus confirmatory evidence from the Phase 2 TORREY study and supportive analyses. If accepted for filing, seralutinib could be eligible for an FDA approval decision in the third quarter of 2027.
Gossamer has reacquired worldwide development and commercial rights to seralutinib from Chiesi following termination of their Collaboration and License Agreement. The termination dissolves the prior U.S. 50/50 profit share and returns ex-U.S. rights to Gossamer. Chiesi will make a one-time $5 million payment to Gossamer and is entitled to a capped royalty on worldwide net sales plus payments upon achievement of specified regulatory and commercial milestones.
At a special meeting held on July 14, 2026, stockholders approved proposals related to the exchange of the company’s 5.00% Convertible Senior Notes due 2027. Through the exchange, Gossamer exchanged approximately $181.1 million of the $200 million aggregate principal amount outstanding for approximately $65.2 million of new 7.50% Convertible Senior Secured First Lien Notes due 2030, along with equity securities and warrants. Stockholders also authorized the board to effect a reverse stock split, which the company expects to implement in or promptly following the third quarter of 2026.
The company reported cash, cash equivalents and marketable securities totaled approximately $57 million as of June 30, 2026.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.
SAN DIEGO - Gossamer Bio, Inc. (NASDAQ:GOSS) plans to submit a New Drug Application for seralutinib in pulmonary arterial hypertension in September 2026, according to a press release statement issued Monday.
The clinical-stage biopharmaceutical company held a Pre-NDA Type B meeting with the U.S. Food and Drug Administration in mid-June 2026 and received official meeting minutes. The FDA characterized the degree of statistical significance and magnitude of treatment effect observed in the Phase 3 PROSERA study as review issues rather than filing issues, the company stated.
The planned NDA submission will be supported by the Phase 3 PROSERA study plus confirmatory evidence from the Phase 2 TORREY study and supportive analyses. If accepted for filing, seralutinib could be eligible for an FDA approval decision in the third quarter of 2027.
Gossamer has reacquired worldwide development and commercial rights to seralutinib from Chiesi following termination of their Collaboration and License Agreement. The termination dissolves the prior U.S. 50/50 profit share and returns ex-U.S. rights to Gossamer. Chiesi will make a one-time $5 million payment to Gossamer and is entitled to a capped royalty on worldwide net sales plus payments upon achievement of specified regulatory and commercial milestones.
At a special meeting held on July 14, 2026, stockholders approved proposals related to the exchange of the company’s 5.00% Convertible Senior Notes due 2027. Through the exchange, Gossamer exchanged approximately $181.1 million of the $200 million aggregate principal amount outstanding for approximately $65.2 million of new 7.50% Convertible Senior Secured First Lien Notes due 2030, along with equity securities and warrants. Stockholders also authorized the board to effect a reverse stock split, which the company expects to implement in or promptly following the third quarter of 2026.
The company reported cash, cash equivalents and marketable securities totaled approximately $57 million as of June 30, 2026.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.
决策记录链 · 只追加
每次领取产生一条记录,重新决策追加一条并以 supersedes 指向被替代的记录(ADR 0014)。
这条决策早于决策账本(2026-10-08 起逐条追加),没有追加记录。